In The Lancet Respiratory Medicine, Luca Richeldi and colleagues report the safety and efficacy of pamrevlumab (FG-3019), a human monoclonal antibody against connective tissue growth factor, in a randomised, double-blind, placebo-controlled phase 2 trial done in patients with idiopathic pulmonary fibrosis. In view of the encouraging observations reported, it should be stressed at the outset that the results must be treated with caution pending an adequately powered phase 3 study. We have been here before: apparently striking treatment effects in idiopathic pulmonary fibrosis have been greeted with enthusiasm, but ultimately led to disappointment, as in an initial report of the efficacy of interferon gamma in idiopathic pulmonary fibrosis, admittedly in a tiny cohort. In a way, idiopathic pulmonary fibrosis trials have been like photography: we have developed from the negatives. Nonetheless, the findings of this latest study are striking on a number of levels.

中文翻译：

---

Pamrevlumab在特发性肺纤维化中。

在柳叶刀呼吸内科，Luca Richeldi及其同事在一项针对特发性肺纤维化患者的随机，双盲，安慰剂对照的2期临床试验中报告了抗结缔组织生长因子的人类单克隆抗体pamrevlumab（FG-3019）的安全性和有效性。鉴于所报告的令人鼓舞的观察，一开始就应强调，在进行充分动力的第3期研究之前，必须谨慎对待结果。我们曾来过这里：热情洋溢地迎来了特发性肺纤维化的明显治疗效果，但最终导致了失望，正如关于γ干扰素在特发性肺纤维化中的疗效的首次报道一样，这在一个很小的队列中是可以肯定的。从某种意义上说，特发性肺纤维化试验就像摄影一样：我们是从阴性开始的。